EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase II)Open Access · CC BY-NC 4.0

Sarilumab in Polyarticular‐Course Juvenile Idiopathic Arthritis: Dose‐Finding and One‐Year Analysis of a Phase 2b, Open‐Label, Multicenter Study

Fabrizio De Benedetti iD, Inmaculada C Penadés, Irina Nikishina, Ivan Foeldvari iD, Alberto J Spindler, Anna Kozlova, Nadina Rubio-Pérez, Pierre Quartier, Zbigniew Żuber, Raul Barria, Daniel Clemente, Gabriel V Cornejo und 8 weitere

Arthritis Care & Research · 2025

DOI: 10.1002/acr.25692 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Arthritis Care & Research, 2025. Verfasst von Fabrizio De Benedetti und 19 weiteren Autor:innen. Beteiligte Einrichtung: Ospedale Pediatrico Bambino Gesù IRCCS, ERN-RITA Center, Rome, Italy. Hauptthemen laut MEDLINE: Arthritis, Juvenile, Antibodies, Monoclonal, Humanized, Antirheumatic Agents. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Regeneron Pharmaceuticals, Sanofi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study assessed sarilumab in treating patients with polyarticular‐course juvenile idiopathic arthritis (pcJIA).

Methods

This phase 2b, open‐label study (NCT02776735) consisted of three sequential parts (each with a core‐treatment and extension‐phase). During part 1, three doses were assessed in two weight groups (Group A/B: ≥30–60 kg/≥10–

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, JuvenileAntibodies, Monoclonal, HumanizedAntirheumatic AgentsHumansFemaleMaleChildTreatment OutcomeAdolescentDose-Response Relationship, DrugChild, PreschoolTime Factors

Substanzen

Antibodies, Monoclonal, HumanizedsarilumabAntirheumatic Agents

Autor:innen und Institutionen

  • Ospedale Pediatrico Bambino Gesù IRCCS, ERN-RITA Center, Rome, Italy.
  • Hospital Universitario y Politécnico la Fe, Valencia, Spain.
  • V. A. Nasonova Research Institute of Rheumatology, Moscow, Russia.
  • Am Schoen Klinik Eilbek, Hamburg, Germany.
  • Centro Médico Privado de Reumatologia, Tucumán, Argentina.
  • Centre of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.

ORCID-Profile: Fabrizio De Benedetti, Ivan Foeldvari, Stephen DiMartino

Förderung

  • Regeneron Pharmaceuticals
  • Sanofi

Zitieren

APA

De Benedetti, F., Penadés, I. C., Nikishina, I., Foeldvari, I., Spindler, A. J., Kozlova, A., Rubio-Pérez, N., Quartier, P., Żuber, Z., Barria, R., Clemente, D., Cornejo, G. V., Marzan, K., Liu, N., Xu, C., DiMartino, S., Giannelou, A., Cao-Ghoul, F., Akinlade, B., & Baret-Cormel, L. (2025). Sarilumab in Polyarticular‐Course Juvenile Idiopathic Arthritis: Dose‐Finding and One‐Year Analysis of a Phase 2b, Open‐Label, Multicenter Study. Arthritis Care & Research. https://doi.org/10.1002/acr.25692

Vancouver

De Benedetti F, Penadés IC, Nikishina I, Foeldvari I, Spindler AJ, Kozlova A, et al. Sarilumab in Polyarticular‐Course Juvenile Idiopathic Arthritis: Dose‐Finding and One‐Year Analysis of a Phase 2b, Open‐Label, Multicenter Study. Arthritis Care & Research. 2025. doi:10.1002/acr.25692

BibTeX
@article{DeBenedetti2025,
  author = {De Benedetti, Fabrizio and Penadés, Inmaculada C and Nikishina, Irina and Foeldvari, Ivan and Spindler, Alberto J and Kozlova, Anna and Rubio-Pérez, Nadina and Quartier, Pierre and Żuber, Zbigniew and Barria, Raul and Clemente, Daniel and Cornejo, Gabriel V and Marzan, Katherine and Liu, Nancy and Xu, Christine and DiMartino, Stephen and Giannelou, Angeliki and Cao-Ghoul, Fei and Akinlade, Bolanle and Baret-Cormel, Lydie},
  title = {Sarilumab in Polyarticular‐Course Juvenile Idiopathic Arthritis: Dose‐Finding and One‐Year Analysis of a Phase 2b, Open‐Label, Multicenter Study},
  journal = {Arthritis Care & Research},
  year = {2025},
  doi = {10.1002/acr.25692}
}
Kostenlos starten →